InsiderDirector
Jean Jacques Bienaime Insider Trading Activity
Every SEC Form 4 transaction reported by Jean Jacques Bienaime, sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Is Jean Jacques Bienaime buying or selling?
Jean Jacques Bienaime reported 17 open-market buys ($1.3M) and 86 sells ($79.0M) across 103 Form 4 filings at 6 companies — a net selling position of $77.7M.
Source: SEC EDGAR Form 4
What stands out
- Jean Jacques Bienaime has reported Form 4 transactions at 6 companies; the most active, BIOMARIN PHARMACEUTICAL INC (BMRN), accounts for 82 of 103 filings (80%).
- The most recent Form 4 was accepted on Aug 19, 2026 (1 months ago).
- In the last 12 months: 11 open-market purchases ($922.3K) and no sales.
- The largest open-market purchase in the last 12 months was $492.7K of Ascendis Pharma A/S (ASND) on Aug 19, 2026. SEC ↗
Key Statistics (as of Aug 19, 2026)
Total Form 4 filings
103
SEC EDGAR
Companies
6
Buys (17)
$1.3M
Sells (86)
$79.0M
Insider sentiment
Net sellingNet insider flow of $77.7M in net selling, filed between Jan 2, 2018 – Aug 19, 2026.
Companies Jean Jacques Bienaime files for
Recent Jean Jacques Bienaime transactions
| Date | Ticker | Role | Type | Shares | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | KROS | Director | Purchase | 1.0K | $10.3K | SEC ↗ |
| Aug 19, 2026 | ASND | Director | Purchase | 2.0K | $492.7K | SEC ↗ |
| Jul 17, 2026 | KROS | Director | Purchase | 1.0K | $10.6K | SEC ↗ |
| Jun 17, 2026 | KROS | Director | Purchase | 1.0K | $10.2K | SEC ↗ |
| Jun 1, 2026 | ASND | Director | Purchase | 500 | $111.6K | SEC ↗ |
| May 27, 2026 | ASND | Director | Purchase | 400 | $95.1K | SEC ↗ |
| May 19, 2026 | KROS | Director | Purchase | 1.0K | $10.6K | SEC ↗ |
| May 19, 2026 | IMNM | Director | Purchase | 5.0K | $103.5K | SEC ↗ |
| Apr 17, 2026 | KROS | Director | Purchase | 1.0K | $11.7K | SEC ↗ |
| Mar 12, 2026 | IMNM | Director | Purchase | 2.0K | $43.7K | SEC ↗ |
| Mar 11, 2026 | KROS | Director | Purchase | 2.0K | $22.4K | SEC ↗ |
| Jun 4, 2025 | IMNM | Director | Purchase | 5.0K | $46.9K | SEC ↗ |
| Mar 26, 2025 | IMNM | Director | Purchase | 7.8K | $60.7K | SEC ↗ |
| Mar 25, 2025 | IMNM | Director | Purchase | 7.0K | $57.5K | SEC ↗ |
| Aug 20, 2024 | IMNM | Director | Purchase | 7.0K | $97.6K | SEC ↗ |
| May 22, 2024 | IMNM | Director | Purchase | 2.0K | $27.1K | SEC ↗ |
| May 13, 2024 | BMRN | Director | Sale | 40.0K | $3.3M | SEC ↗ |
| Apr 15, 2024 | BMRN | Director | Sale | 40.0K | $3.6M | SEC ↗ |
| Mar 7, 2024 | BMRN | Director | Sale | 2.0K | $172.2K | SEC ↗ |
| Feb 29, 2024 | BMRN | Director | Sale | 1.0K | $90.3K | SEC ↗ |
| Feb 12, 2024 | BMRN | Director | Sale | 30.0K | $2.7M | SEC ↗ |
| Aug 9, 2023 | BMRN | Chief Executive Officer | Sale | 10.0K | $882.1K | SEC ↗ |
| May 15, 2023 | BMRN | Chief Executive Officer | Sale | 30.0K | $2.8M | SEC ↗ |
| Apr 10, 2023 | BMRN | Chief Executive Officer | Sale | 10.0K | $961.3K | SEC ↗ |
| Mar 14, 2023 | BMRN | Chief Executive Officer | Sale | 23.0K | $2.1M | SEC ↗ |
Showing the 25 most recent filings of 103. Screen every filing.
Jean Jacques Bienaime insider trading FAQ
Is Jean Jacques Bienaime buying or selling?
Across 103 SEC Form 4 filings, Jean Jacques Bienaime reported 17 open-market purchases totaling $1.3M and 86 sales totaling $79.0M — a net selling position of $77.7M.
Which companies does Jean Jacques Bienaime file Form 4s for?
Jean Jacques Bienaime has reported insider transactions at 6 companies, most often BIOMARIN PHARMACEUTICAL INC (BMRN), Immunome Inc. (IMNM), Keros Therapeutics, Inc. (KROS), Ascendis Pharma A/S (ASND), INCYTE CORP (INCY).
How far back does Jean Jacques Bienaime's filing history go?
Trabud holds Jean Jacques Bienaime's SEC Form 4 filings from Jan 2, 2018 – Aug 19, 2026, sourced directly from SEC EDGAR.
Where does Trabud get Jean Jacques Bienaime's insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track Jean Jacques Bienaime and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener